Search Results

NanoString Technologies, Inc. (“NanoString” or “the Company”) today announced that substantially all of its assets will be acquired by Bruker Corporation (“Bruker”), a global life science analytical instrument company, for approximately $392.6 million in cash consideration, plus the assumption of certain liabilities.

Bruker Corporation announced that it has closed its asset acquisition of the business of NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of life-science research solutions for spatial transcriptomics and gene expression analysis.

Bruker Corporation announced that it has entered into a definitive acquisition agreement with NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of solutions for spatial transcriptomics and gene expression analysis.

NanoString Technologies, Inc. announced that it has reached an agreement with Patient Square Capital, a prominent health care investment firm, pursuant to which Patient Square will serve as the “stalking horse” bidder in conjunction with a court-supervised sales process.

NanoString Technologies, Inc. announced the release of the first public dataset of the whole transcriptome obtained at true single-cell resolution on the CosMx™ Spatial Molecular Imager.

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2023.

NanoString Technologies, Inc. announced the Company has entered into a credit agreement with its existing lenders comprised of $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S.

NanoString Technologies, Inc. announced that steps are being taken to protect its business, customers, employees and its mission to “Map the Universe of Biology.” With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas. The conference will be held in San Diego, April 5-10, 2024.

NanoString Technologies, Inc. announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences.